A number of firms have modified their ratings and price targets on shares of Spark Therapeutics (NASDAQ: ONCE) recently: 5/19/2016 – Spark Therapeutics had its “underperform” rating reaffirmed by analysts at Wedbush. They now have a $21.00 price target on the stock. 5/19/2016 – Spark Therapeutics had its “buy” rating reaffirmed by analysts at Cowen […]
